Flatiron compiles rich data on the uptake of PD-1 inhibitor drugs; A case study in real-world evidence?

From the desk of Kimryn Rathmell: What to read before these beautiful days slip away
My summer reading challenged me to see people, purpose, and complexity in a new way

One of the great pleasures of summer is having more time to read.

August 14, 2026

The defining question of the next decade is not how many drug candidates can be generated, but who decides which ones move forward, and why
Drug development must convene a forum for candid, cross-sector discussion

At the 2026 Annual Meeting of the American Society of Clinical Oncology in Chicago, results from the phase III HARMONi-6 trial were presented at the plenary session and published simultaneously in The Lancet. The HARMONi-6 trial tested a novel bispecific antibody that engages PD-1 and VEGF (ivonescimab), given with platinum-doublet chemotherapy to patients with previously untreated advanced squamous non-small cell lung cancer.

August 14, 2026

By Richard L. Schilsky, H. Kim Lyerly, Thomas R. Fleming and Renzo Canetta

Clinical Guest Editorial

Like it or not, AI psycho-oncology care is already happening. Urgently needed: An ethical framework
Developers and mental health providers must share the same goal: Safe, equitable, trustworthy, and patient-centered care

In 2026, more than 900 million people are estimated to be regularly using generative artificial intelligence—computer systems capable of creating human-like text, images, audio, video, and other original content. AI is becoming integrated into nearly every aspect of daily life. Health care is no exception.

August 14, 2026

By Viktor Clark, Sean M. Dozier, AnnaLynn M. Williams, Cynthia M. Rand and Lee A. Kehoe

Remote robotic surgery could redefine access to expert cancer care

For generations, geography has been one of the biggest barriers to specialized surgical care. Advances in robotic surgery, telecommunications and cybersecurity may soon make distance far less relevant.

August 14, 2026

By Yuman Fong

Cancer Policy

Trump’s vaccine executive order draws criticism from medical community, may put cancer populations at risk

President Trump earlier this week issued an executive order that would drastically change the childhood immunization schedule—limiting recommendations, spacing out shots, and splitting the combined measles, mumps, and rubella vaccine into single-disease injections.

August 14, 2026

By Claire Marie Porter

Cancer Policy

Senate passes stopgap bill that would ban OMB from finalizing rule that would politicize science

The U.S. Senate has passed a stopgap spending bill that, in addition to avoiding a government shutdown at the end of September, would preclude the White House Office of Management and Budget from finalizing a proposal that seeks to fundamentally redraw the ground rules for all federally funded research (The Cancer Letter, Aug. 7, 2026).

August 14, 2026

By Sara Willa Ernst

Flatiron compiles rich data on the uptake of PD-1 inhibitor drugs;

A case study in real-world evidence?

YOU MAY BE INTERESTED IN

From the desk of Kimryn Rathmell: What to read before these beautiful days slip away
My summer reading challenged me to see people, purpose, and complexity in a new way

The defining question of the next decade is not how many drug candidates can be generated, but who decides which ones move forward, and why
Drug development must convene a forum for candid, cross-sector discussion

Like it or not, AI psycho-oncology care is already happening. Urgently needed: An ethical framework
Developers and mental health providers must share the same goal: Safe, equitable, trustworthy, and patient-centered care

Remote robotic surgery could redefine access to expert cancer care

Trump’s vaccine executive order draws criticism from medical community, may put cancer populations at risk

Senate passes stopgap bill that would ban OMB from finalizing rule that would politicize science

Renew today!

Subscriber content

Never miss an issue!

Login

Flatiron compiles rich data on the uptake of PD-1 inhibitor drugs;

A case study in real-world evidence?

YOU MAY BE INTERESTED IN

From the desk of Kimryn Rathmell: What to read before these beautiful days slip awayMy summer reading challenged me to see people, purpose, and complexity in a new way

The defining question of the next decade is not how many drug candidates can be generated, but who decides which ones move forward, and whyDrug development must convene a forum for candid, cross-sector discussion

Like it or not, AI psycho-oncology care is already happening. Urgently needed: An ethical frameworkDevelopers and mental health providers must share the same goal: Safe, equitable, trustworthy, and patient-centered care

Remote robotic surgery could redefine access to expert cancer care

Trump’s vaccine executive order draws criticism from medical community, may put cancer populations at risk

Senate passes stopgap bill that would ban OMB from finalizing rule that would politicize science

Never miss an issue!

Login

From the desk of Kimryn Rathmell: What to read before these beautiful days slip away
My summer reading challenged me to see people, purpose, and complexity in a new way

The defining question of the next decade is not how many drug candidates can be generated, but who decides which ones move forward, and why
Drug development must convene a forum for candid, cross-sector discussion

Like it or not, AI psycho-oncology care is already happening. Urgently needed: An ethical framework
Developers and mental health providers must share the same goal: Safe, equitable, trustworthy, and patient-centered care